| HOME >> MEDICINE >> TECHNOLOGY |
7,9577,987 Total assets$
415,635$
473,170 Liabilities and equity Current liabilities: Accounts payable$
20,668$
8,209 Accrued compensation
12,80923,071 Other accrued liabilities
28,65731,646 Customer advances
18,57618,177 Deferred revenue—current87,27283,071 Total current liabilities167,982174,174 Long-term liabilities: Long-term other liabilities
5,2935,988 Deferred revenue—noncurrent9,9689,675 Long-term debt
81,56579,466 Total liabilities264,808269,303 Equity: Preferred stock, $0.001 par value; authorized: 5,000,000 shares; no shares issued and outstanding
-- Common stock, $0.001 par value; authorized: 200,000,000 and 100,000,000 shares; issued and outstanding: 73,920,824 and 71,864,268 shares at December 31 and June 30, 2012, respectively
7472 Additional paid-in capital418,008409,143 Accumulated other comprehensive income
2,4732,837 Accumulated deficit(269,728)(216,427) Total stockholders' equity
150,827195,625 Noncontrolling interest 8,242 Total equity
150,827203,867 Total liabilities and equity
$
415,635$
473,170
Non-GAAP Financial MeasuresThis press release includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission, with respect to the three and six months ended December 31, 2012 and 2011. "GAAP" refers to generally accepted accounting principles in the United States.
Accuray closed the acquisition of TomoTherapy on June 10, 2011 and TomoTherapy's operations since that date are included in Accuray's consolidated results of operations. Accounting for the impact of this acquisition has resulted in
'/>"/>
| SOURCE Accuray Incorporated Copyright©2012 PR Newswire. All rights reserved |